



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  <small>(to be used for all correspondence after initial filing)</small>	Application Number	10/554,036
	Filing Date	October 20, 2005
	First Named Inventor	Besidski
	Art Unit	Unknown
	Examiner Name	Unknown
Total Number of Pages in This Submission	7	Attorney Docket Number 101023-1P US

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement  <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below): Forms PTO/SB/08A & PTO/SB/08B 27 References
<div style="border: 1px solid black; padding: 2px;">Remarks</div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	AstraZeneca		
Signature			
Printed name	Kenneth F. Mitchell		
Date	March 14, 2006	Reg. No.	42,007

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:			
Signature			
Typed or printed name	Marie M. Greloch	Date	3-14-06

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Appl. No.: 10/554,036

Confirmation No.: Unknown

Applicant: Besidski *et al.*

PCT Appl. No.: PCT/SE2004/000635

National Phase Fld (371): October 20, 2005

PCT Filed: April 26, 2004

Docket No.: 101023-1P US

TC/A.U.: Unknown

Customer No.: 22466

Examiner: Unknown

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

Applicants submit herewith a list of patents and publications for which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56.

In accordance with 37 C.F.R. §§ 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

In accordance with the U.S. Patent Office's partial waiver of the requirement under 37 C.F.R. 1.98(a)(2)(i), only copies of the foreign patent documents and non-patent publications are enclosed.

This Information Disclosure Statement is being filed before the mailing date of a first office action on the merits and therefore, pursuant to 37 C.F.R. § 1.97(b), no fee is required pursuant to 37 C.F.R. § 1.17(p). However, if any fees should be due, authorization is given to charge deposit account 260166 for the required fees.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "K F Mitchell", written over a horizontal line.

Kenneth F. Mitchell  
Reg. No.42,007  
302-886-7466

Dated:

March 14 2006

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(Use as many sheets as necessary)*

Sheet	1	of	2
-------	---	----	---

**Complete if Known**

Application Number	10/554,036
Filing Date	October 20, 2005
First Named Inventor	Besidski
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	101023-1P US

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	A4	EP 0599382	06-01-1994	Eastman Kodak Company		
	A5	EP 0599384	06-01-1994	Eastman Kodak Company		
	A6	WO 94/14801	07-07-1994	Smithkline Beecham PLC		
	A7	WO 01/12188	02-22-2001	Pharmacia & Upjohn et al.		
	A8	WO 02/090326	11-14-2002	Smithkline Beecham PLC		
	A9	WO 02/42273	05-30-2002	Bristol-Myers Squibb Co.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**

**TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**  
*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/554,036
		Filing Date	October 20, 2005
		First Named Inventor	Besidski
		Art Unit	Unknown
		Examiner Name	Unknown
Sheet 1	of 2	Attorney Docket Number	101023-1P US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A15	FREY, C. et al., "Iminoisoindolinone metal complexes, method for...high-molecular-weight material...containing such a metal complex," & EP, 23889, 19810211, accessn1981:444733	
	A16	MILLER, R. et al., "Schistosoma mansoni: salicylanilides... cercarial penetration of mice," & Experimental Parasitology, 61(3), ppg. 359-68, 1956, accession no. 1986:472101	
	A17	PORTNAYA, B. et al., "Azomethine dyes. IV. Indoaniline...heterocyclic N-substituted 1-hydroxy-2-naphthamides," & Ts. Vses. Nauchn.-Issled. Kinnofotoinst. (No. 40) 106-18, 1960	
	A18	SHINKAI, H. et al., "Preparation of amide derivatives as nociception antagonists," & WO, A1, 9948492, 19990930, pp. 113, accession no. 1999:626041	
	A19	SUZUKI, N. et al., "Preparation of imidazole derivatives as gonadotropinreleasing hormone antagonists," & JP, A2, 2000095767, 20000404, pp. 79, accession no. 132:265201	
	A20	CHEMCATS, Accession No. 2001:53212, 24 April 2003, 3-Pyridinecarboxamide,N-(2-methyl-5-benzothiazolyl), CASRN 302953-34-0	
	A21	WILLITZER, H. et al., "Synthesis and antiviral activity of substituted 5-ureido- and 5-thioureidobenzimidazole derivatives," & Pharmazie, 33(1), 30-8, 1978	
	A22	Caterina, M.J., Schumacher, M.A., et. al., Nature 1997 vol. 389, pgs 816 - 824	
	A23	Tominaga, M., Caterina, M.J., et al., Neuron 1998, vol. 21 pgs 531 - 543	
	A24	Walker, et al., J. Pharmacol Exp Ther. 2003 Jan; 304(1):56-62	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.  
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/554,036
		Filing Date	October 20, 2005
		First Named Inventor	Besidski
		Art Unit	Unknown
		Examiner Name	Unknown
Sheet 2	of 2	Attorney Docket Number 101023-1P US	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A25	Rashid, et al, J Pharmacol Exp Ther. 2003 March;304(3):940-948	
	A26	Hwang and Oh Curr Opin Pharmacol 2002 June; 2(3):235-242	
	A27	Yiangou, et al BJU Int 2001 june; 87(9): 774-779, Szallasi Am J Clin Pathol 2002 118: 110-121	
	A28	STN International, Caplus Acces No. 2004:101143, document no. 140:146168, Moriya, Minoru, et al; "Antagonist of . . . Active Ingredient"; & WO, A1, 2004011440, 20040205, 112	
	A29	STN International File Registry, January 2001	
	A30	Mark E. McDonnell, et al.; Bioorganic & Medicinal Chemistry Letters 14 (2004); pages 531-534	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.